SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Jack Mallers resigned as CEO and director effective July 20, 2026, with a separation agreement providing cash payments and vested equity. While the filing also discloses Raphael Zagury's appointment as CEO, the principal disclosed action centers on Mallers' departure—the triggering event that necessitated the leadership transition. The departure is material to a reasonable investor assessing the registrant's leadership continuity.
View raw filing on EDGAR →PolyPid has entered into an exclusive commercial partnership agreement with Azurity Pharmaceuticals for D-PLEX100 commercialization in the U.S. and Canada. The agreement involves substantial financial consideration ($30 million upfront and near-term, plus up to $300 million in milestone payments and tiered royalties), transfer of commercial rights, and manufacturing obligations. This constitutes a material disposition of commercial rights and a significant strategic transaction that would affect a reasonable investor's assessment of the company's value and future revenue streams.
View raw filing on EDGAR →Planet Green's subsidiary Shanghai Shuning entered into a comprehensive digital marketing services contract with iFLYTEK running through December 2026. The press release emphasizes this as a "significant milestone" and "significant new marketing contract" that "significantly strengthens our revenue pipeline" and positions the company as a premier service provider for tier-one technology clients. While this is a material business development event for the company's digital marketing segment, it does not fit neatly into the specific event-type taxonomy (not M&A, not a material impairment, not a restructuring). It is clearly operational in nature—a new material contract win—making operational_other the most appropriate classification.
View raw filing on EDGAR →Constantine Dakolias was appointed as a director and audit committee member of Bleichroeder Acquisition Corp. III effective July 20, 2026. The disclosure centers on the appointment of a qualified independent director with extensive investment and credit management experience, making this a clear executive appointment event material to investors evaluating the company's governance and board composition.
View raw filing on EDGAR →The filing discloses the Board's nomination of Mr. Ng Tsze Lun for election as a director and his appointment as Chairman of the Board effective after stockholder approval at the 2026 annual meeting. While the filing also mentions Mr. Choi Lin Hung's decision not to stand for re-election as director and Chairman, the principal disclosed action centers on the appointment of Mr. Ng to the Chairman role. The press release reinforces this as a "Board Leadership Transition" with Mr. Ng succeeding Mr. Choi as Chairman, making the appointment the salient event.
View raw filing on EDGAR →This is a monthly operational and production update disclosing material business metrics and strategic developments: Bitcoin production increased 388% Y/Y to 990 BTC, AI Cloud ARR grew to ~$76M at 95% utilization, self-mining hashrate reached 73.0 EH/s, and the company announced groundbreaking of a Sealminer manufacturing facility in Nevada and execution of a 10-year lease for 21.7 IT MW in Malaysia. These operational milestones and capacity expansions would materially affect a reasonable investor's assessment of the company's growth trajectory and infrastructure development, though the disclosure is operational rather than financial results, M&A, or governance in nature.
View raw filing on EDGAR →The filing discloses two operational developments: (1) preparation and filing of investor presentation materials outlining the Company's three technology platforms and strategic direction, and (2) announcement of a joint venture with Placeve Inc. via press release. While the presentation materials are routine corporate communications, the joint venture announcement represents a material strategic partnership that would affect a reasonable investor's assessment of the Company's operational direction and growth strategy. This is an operational/strategic event that does not fit the specific categories of M&A activity, debt issuance, or other named types, making operational_other the most appropriate classification.
View raw filing on EDGAR →This press release announces positive clinical trial results for Alpha DaRT in combination with pembrolizumab in head and neck cancer, demonstrating a 100% objective response rate and 18.2-month median overall survival that exceed pre-specified thresholds and historical benchmarks. While the disclosure reports clinical progress rather than a discrete corporate event (M&A, executive change, debt issuance, etc.), the achievement of a major clinical milestone with favorable efficacy and safety data in a key indication materially advances the company's pipeline and regulatory strategy, directly supporting its stated plan to pursue larger U.S. studies in discussion with the FDA.
View raw filing on EDGAR →Cadrenal announced a comprehensive strategic realignment of its clinical portfolio into a "Cardiac Acute Critical Care Franchise" and initiated a structured process to secure out-licensing, portfolio monetization, or commercial co-development partnerships for late-stage assets. This represents a material shift in the company's business model and operational strategy—from internal development to a partnership-driven model—which would affect a reasonable investor's assessment of the company's path to commercialization and capital efficiency. While the filing does not disclose a completed M&A transaction or specific partnership agreement, the strategic portfolio reorganization and active partnering process constitute a material operational and strategic business event.
View raw filing on EDGAR →Change Agents Corporation (formerly Avalon GloboCare Corp.) completed a corporate name change and corresponding Nasdaq ticker symbol change from ALBT to CHGA, effective July 22, 2026. The name and symbol change reflects the company's strategic repositioning and is material to investors as it affects trading identification, though no stockholder approval was required and the change does not affect stockholder rights.
View raw filing on EDGAR →Virtuix amended three warrants to reduce the exercise price from $3.00 to $2.50 per share during a specified period (July 21 – August 27, 2026), making the warrants more likely to be exercised and diluting existing shareholders. While technically an amendment to existing warrants rather than a new issuance, the material reduction in exercise price substantially increases the probability of dilution and is economically equivalent to a dilutive capital event. The filing under Item 1.01 (Material Definitive Agreement) and the involvement of a significant investor (Streeterville Capital) underscore materiality.
View raw filing on EDGAR →The 6-K discloses a change in ticker symbol from YOOV to CIGL, effective July 21, 2026, on the Nasdaq Capital Market. While a ticker change alone is not necessarily a delisting event, it often signals a transfer of listing or a change in market tier (e.g., from Nasdaq Global Market to Nasdaq Capital Market, or vice versa). The disclosure of a "new ticker symbol" and the specific effective date suggest a material change in the registrant's listing status that would affect investor identification and trading of the security.
View raw filing on EDGAR →SuperX announced a strategic partnership with Mercuria Asia involving a material investment through a convertible note and warrant subscription agreement. While structured as a "partnership" rather than a traditional acquisition or merger, the convertible note and warrant issuance represents a significant capital transaction and equity dilution that would materially affect investor assessment. The press release emphasizes this as a "significant milestone in SuperX's global expansion" with long-term strategic implications for the company's infrastructure development and profitability.
View raw filing on EDGAR →The 6-K discloses a series of voluntary corporate governance enhancements by Charming Medical's board, including: (1) a lock-up agreement by majority shareholder and CEO Ms. Kit Wong restricting share sales for one year; (2) the company's election to abandon foreign private issuer exemptions and comply fully with Nasdaq domestic governance standards; and (3) the irrevocable surrender and cancellation of all Class B Ordinary Shares (held by Ms. Wong), eliminating the dual-class voting structure and reducing her voting power from ~91.25% to ~68.19%. These measures materially affect shareholder governance rights and the company's capital structure and listing compliance posture.
View raw filing on EDGAR →The 6-K discloses the appointment of Mr. Nazario Matachione as a member of the Board of Directors of RoyaLand Company, Ltd. effective July 16, 2026. The filing explicitly states "the Board of Directors of The RoyaLand Company, Ltd. (the "Company") appointed Mr. Nazario Matachione as a member of the Board" and provides extensive biographical detail on his qualifications and experience. This is a clear executive appointment to the board, material to investors assessing the company's governance and leadership.
View raw filing on EDGAR →The filing discloses results of a shareholder vote at an annual meeting held on July 21, 2026, where shareholders approved all proposals including an amendment to extend the SPAC's deadline to complete an initial business combination. This is a direct disclosure of shareholder vote results under Item 5.07, and the extension approval is material to investors as it affects the timeline and viability of the proposed business combination with a critical mineral target company announced on July 17, 2026.
View raw filing on EDGAR →This press release announces a follow-on order for ParaZero's DefendAir Pods for integration into an autonomous Counter-UAS operational system protecting critical infrastructure. The disclosure is a business development event—a material customer order—that does not fit the specific event-type taxonomy (not M&A, not a financial obligation, not a results announcement). It is clearly operational in nature, reflecting commercial traction and market validation for the company's core product line, and would be material to a reasonable investor assessing the company's revenue prospects and market adoption.
View raw filing on EDGAR →Mr. Niels Brix, an independent director since December 2021, resigned from the board and all committees effective immediately on July 7, 2026. The resignation was triggered by a lapse in the Company's directors and officers (D&O) insurance coverage, which the Company has since restored. This is a clear executive departure under Item 5.02, material because it involves loss of board representation and reflects a governance control failure (lapsed insurance).
View raw filing on EDGAR →The filing discloses that XTL Biopharmaceuticals has regained compliance with Nasdaq listing rules after a prior delisting threat, but remains subject to a one-year mandatory panel monitor with heightened consequences: any future breach of the Equity Rule will result in immediate delisting without cure rights. This is material because it signals ongoing listing vulnerability and constrains the company's operational flexibility during the monitoring period.
View raw filing on EDGAR →This press release addresses "unusual trading activity" in the Company's securities, with the Company confirming it is "not aware of any material non-public information" that would explain the price and volume movements. While the Company states its business continues in the ordinary course with no undisclosed corporate developments, the fact that management felt compelled to issue a public statement in response to significant trading volatility—and to confirm the absence of material non-public information—suggests an event material to investors' assessment of the registrant. The disclosure does not fit neatly into any specific event category (not an earnings release, executive change, M&A, restatement, or other named type), but the trading anomaly and management's response would affect a reasonable investor's evaluation of the stock and the company's transparency.
View raw filing on EDGAR →Vicarious Surgical Inc. entered into a general assignment for the benefit of creditors (ABC) on July 21, 2026, transferring substantially all assets to a liquidation entity. This non-judicial insolvency proceeding is functionally equivalent to bankruptcy and represents a terminal event materially threatening the registrant's continued existence.
View raw filing on EDGAR →Stockholders voted on July 21, 2026 to approve an assignment for the benefit of creditors followed by voluntary dissolution and liquidation, with 13,348,600 votes in favor, 100,879 against, and 44,093 abstentions (69% quorum of outstanding voting power).
View raw filing on EDGAR →All seven board members resigned effective upon Form 15 filing, and four key executives—CEO Stephen From, President Adam Sachs, CTO Sammy Khalifa, and Chief Medical Officer Dr. Barry Greene—were terminated effective July 21, 2026, in connection with the company's liquidation.
View raw filing on EDGAR →The filing discloses an Extraordinary General Meeting on July 17, 2026, where shareholders approved multiple governance amendments: (1) extension of the business combination deadline to August 2, 2027; (2) trust interest withdrawal amendment allowing up to $0.10 per share withdrawal; (3) company name change from M3-Brigade Acquisition V Corp. to Velos Acquisition I Corp.; and (4) issuance of a $3.5M promissory note to the sponsor. While Item 1.01 addresses the trust agreement amendment and promissory note, and Item 5.07 reports shareholder vote results, the central disclosed event is the shareholder approval of multiple governance and capital structure amendments at an extraordinary meeting. This is material to investors as it affects the company's timeline, capital structure, and governance, but the primary domain is governance (shareholder votes, articles amendments, name change) rather than a specific financial or operational event type.
View raw filing on EDGAR →Getty Images appointed two new independent directors—Elizabeth Abrams and Thomas Walper—to its Board of Directors effective July 20, 2026. Ms. Abrams was also appointed to the Audit Committee, and both directors entered into independent director agreements providing monthly fees of $50,000 plus additional compensation.
View raw filing on EDGAR →Getty Images engaged Guggenheim Securities as a financial advisor to evaluate strategic financing alternatives and balance sheet management initiatives. This preliminary disclosure signals potential material corporate action such as debt restructuring, capital raising, or M&A activity.
View raw filing on EDGAR →Nasdaq Listing Qualifications Staff issued a determination letter on July 16, 2026 to delist the Company's common stock and warrants based on violations of Nasdaq Listing Rules 5205(e) and 5250(a)(1) related to disclosures regarding China Securities Regulatory Commission review status. The Company intends to appeal by July 23, 2026, but faces immediate delisting if the Panel reaches a unanimous decision against it.
View raw filing on EDGAR →Treasure Global Inc's subsidiary Tadaa Capital entered into a Share Sale Agreement to acquire 80% of Cigar Secret Sdn. Bhd. for RM2.5 million (~$612k USD), giving the purchaser majority control and management rights of a retail tobacco business, with closing subject to conditions and a long-stop date of August 31, 2026.
View raw filing on EDGAR →The Company may issue shares of common stock to satisfy a RM2,250,000 (approximately US$550,795.60) deposit obligation under the Share Sale Agreement, with shares calculated based on currency conversion and closing price, subject to a six-month trading restriction under Regulation S.
View raw filing on EDGAR →Lisa Bollinger, MD, Chief Medical Officer, resigned from her position effective immediately on July 19, 2026. The disclosure centers on the departure of a named executive officer from a key leadership role overseeing clinical and regulatory functions at a therapeutics company. While the company states it does not anticipate impact on clinical timelines, the departure of a CMO is material to investors assessing the company's development capabilities and execution risk.
View raw filing on EDGAR →The 6-K discloses the dismissal of KD & Co. as the Company's independent registered public accounting firm on July 21, 2026, and the simultaneous appointment of HTL CPAs & Business Advisors as the new auditor, effective immediately. This is a clear auditor change event. The filing explicitly states there were no disagreements, adverse opinions, or reportable events, indicating a routine transition rather than a conflict-driven change, but the change itself is material to investors' assessment of audit continuity and financial reporting oversight.
View raw filing on EDGAR →AMR Resources Acquisition Corp. consummated its initial public offering on July 16, 2026, raising $260 million in gross proceeds through the issuance of 25 million units (plus 1 million from over-allotment exercise). The IPO established the blank-check company's foundational structure and material agreements (underwriting, warrant, sponsor, trust, registration rights, and private placement agreements) for future business combinations.
View raw filing on EDGAR →AMR Resources Acquisition Corp. issued unregistered private placement units simultaneously with the IPO closing: 447,500 Sponsor Private Placement Units ($4.475M) and 260,000 Underwriter Private Placement Units ($2.6M), both pursuant to Section 4(a)(2) exemption. These dilutive private placements materially affect capitalization and investor ownership.
View raw filing on EDGAR →Three independent directors—Andrew Childs, Michael Westerman, and Karl Simich—were appointed to the board of AMR Resources Acquisition Corp. in connection with the IPO on July 16, 2026, with assignments to the Audit and Compensation Committees.
View raw filing on EDGAR →Yakov Baranes, a board member of Charging Robotics Inc., tendered his resignation from the Board effective immediately on July 21, 2026. This is a clear departure of a director, which is material to investors as it affects board composition and governance. The disclosure explicitly states the resignation was for personal reasons and not due to disagreement, which is standard boilerplate but does not diminish the materiality of the board change itself.
View raw filing on EDGAR →The filing discloses termination of a Business Combination Agreement between FACT II Acquisition Corp. and Precision Aerospace & Defense Group, Inc., dated November 26, 2025 and amended May 17, 2026, terminated on July 16, 2026. Item 1.02 explicitly addresses "Termination of a Material Definitive Agreement," and the press release confirms the termination of the proposed business combination. This is a material M&A event—the termination of a previously announced merger transaction—which materially affects the registrant's strategic direction and investor expectations.
View raw filing on EDGAR →Bank of Chile placed JPY 10 billion in bonds under its Medium Term Notes Program with a maturity date of July 30, 2029, at 2.32% average rate. This is a direct creation of a new financial obligation through debt issuance in the offshore market, disclosed as Material Information to the Chilean Financial Market Commission. The amount and terms are clearly specified, making this a material debt issuance event.
View raw filing on EDGAR →The 6-K discloses the results of Ohmyhome Limited's Annual General Meeting held on July 21, 2026, where shareholders voted on eleven proposals. The filing presents voting tallies (For/Against/Abstain) for each proposal, including material capital structure changes (authorized share capital increase, capital reduction, share subdivision, share consolidation), director re-appointments, and auditor ratification. This is a classic shareholder_vote_results disclosure under Item 5.07 equivalent, and the capital restructuring proposals are material to investors' assessment of the company's share structure and dilution risk.
View raw filing on EDGAR →Dr. Lynne Fahey McGrath, a director since the Company's June 2021 IPO, passed away on July 20, 2026. This constitutes a departure of a director from the Board due to death. The disclosure is material as it affects the composition of the Board and the loss of a long-serving director with significant biopharmaceutical expertise, which would affect a reasonable investor's assessment of the Company's governance and leadership.
View raw filing on EDGAR →Hercules Capital disclosed preliminary Q2 2026 quarterly financial results, including NAV per share of $12.10–$12.20, net realized gains of $7.7 million, net investment income per share of $0.49–$0.51, and total investments at fair value of $4.5–$4.6 billion, pending final closing procedures.
View raw filing on EDGAR →América Móvil announced entry into a share purchase agreement to acquire 100% of WOW Tel S.A.C., a Peruvian fixed-line telecommunications provider, through its subsidiary. This is a material acquisition subject to regulatory approval by INDECOPI. The transaction represents a direct M&A activity under Item 1.01 of the 8-K taxonomy (or equivalent 6-K disclosure), involving entry into a definitive agreement for a material acquisition.
View raw filing on EDGAR →The 6-K discloses a "Consolidated Synthetic Voting Map" for an Extraordinary General Meeting scheduled for July 22, 2026, presenting consolidated remote voting instructions received by shareholders on items 2 and 3 (election of Board of Directors and Chairman). While technically pre-vote disclosure rather than final results, this represents material shareholder voting information on board composition and leadership—a governance matter affecting reasonable investor assessment of the company's direction and control.
View raw filing on EDGAR →This 6-K discloses a customer order announcement: Luxair has converted three purchase rights into firm orders for E190-E2 aircraft and secured one additional purchase right, bringing its firm E2 order book to nine aircraft. This is a material operational/commercial event reflecting customer demand and revenue recognition for Embraer's Commercial Aviation segment, but it does not fit the specific categories of M&A activity, earnings release, or other named event types. The announcement demonstrates market traction for the E2 platform and is significant to investors assessing Embraer's commercial aviation business performance.
View raw filing on EDGAR →Embraer announced an agreement with Abra Group for the purchase of up to 45 E195-E2 aircraft (20 firm orders plus 10 options and 15 purchase rights), with first deliveries expected in Q4 2027. This constitutes a material commercial transaction that will be included in Embraer's Q3 backlog and represents significant revenue recognition for the registrant. The announcement explicitly states the order will be included in backlog once conditions are fulfilled, making this a discrete M&A/commercial activity event material to investors assessing Embraer's order book and future revenue.
View raw filing on EDGAR →Embraer announced that Binter has placed an additional order for five E195-E2 aircraft with four purchase rights. This is a material commercial contract or order announcement—a discrete operational/business event reflecting customer demand and revenue recognition. While not fitting the specific categories of M&A, earnings, or executive changes, it is clearly material to investors as it demonstrates ongoing commercial success and backlog growth for the company's core Commercial Aviation segment.
View raw filing on EDGAR →Pampa Energía announced approval of its RDA Project's adherence to Argentina's RIGI (Incentive Regime for Large Investments) by Ministry of Economy Resolution No. 1025/2026, qualifying it as a Long-Term Strategic Export Project. The project involves a US$4.522 billion investment in developing the Vaca Muerta formation with 259 horizontal wells, processing facilities, and infrastructure through 2041, with expected export revenues of approximately US$17 billion. This is a material operational and strategic milestone—a major capital project with significant long-term revenue implications and government incentive approval—but does not fit the discrete event categories (not M&A, not a financing event, not a restructuring), making it operational_other.
View raw filing on EDGAR →This is Vale's Q2 2026 production and sales announcement, disclosing detailed operational metrics across iron ore, copper, and nickel segments with year-over-year and quarter-over-quarter comparisons. The document presents production volumes (e.g., iron ore 84.3 Mt, copper 98.4 kt, nickel 42.0 kt), sales figures, price realizations, and forward guidance for 2026, which are the hallmarks of a quarterly earnings/results release. While the filing lacks a formal income statement, the operational and pricing data constitute material financial disclosure affecting investor assessment of Vale's performance and outlook.
View raw filing on EDGAR →Braskem is responding to a B3 inquiry about press reports of debt restructuring negotiations involving approximately R$50 billion in debt. The company confirms it is engaged in a capital structure reorganization with creditors, has obtained a court-ordered stay of enforcement actions for 60 days, and is receiving non-binding restructuring proposals from creditor groups. While the filing does not explicitly state a covenant breach, the combination of a precautionary injunctive relief proceeding, court-ordered stay of creditor enforcement, and active debt restructuring negotiations strongly suggests the company is in financial distress and likely facing or anticipating covenant violations that triggered the need for judicial intervention and creditor negotiations.
View raw filing on EDGAR →The filing discloses the issuance of consolidated obligation bonds totaling $1.0 billion ($400 million and $600 million) by the Federal Home Loan Bank of San Francisco, with trade dates of 7/16/2026 and settlement on 7/20/2026. Schedule A details the specific debt securities issued, including maturity dates, coupon rates, and call provisions. This is a direct creation of a financial obligation under Item 2.03, and the filing explicitly states that "consolidated obligations issuance is material to the Bank."
View raw filing on EDGAR →The filing discloses the creation of direct financial obligations through the issuance of consolidated obligation bonds and discount notes by the Federal Home Loan Bank of Des Moines. Schedule A details multiple debt securities issued on trade dates in July 2026, including variable-rate floaters and fixed-rate bonds totaling approximately $3.39 billion in principal. This is a classic debt issuance disclosure under Item 2.03, and the Bank explicitly acknowledges that "consolidated obligations issuance is material to the Bank."
View raw filing on EDGAR →